LUCD

Lucid Diagnostics offers asymmetric upside, with Medicare reimbursement as a near-term inflection point unlocking a $2–3M backlog and accelerating $8.7M quarterly billable demand. Strong underlying test volume growth, expanding VA access to 9M patients at $1,938/test, and a cash runway into 2027 support LUCD's commercial trajectory. Despite a 1Q26 net loss of $23.6M (impacted by a $9.7M preferred dividend), the non-GAAP loss was $10.5M, reflecting stable underlying cost control and $45M pro forma cash.

Lucid Diagnostics Inc. (LUCD) Shareholder/Analyst Call Prepared Remarks Transcript

Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission Lucid Diagnostics continued building commercial momentum and strengthened its balance sheet ahead of key upcoming reimbursement milestones PAVmed advanced its relaunched medical device portfolio; evaluation of additional acquisition opportunities ongoing Conference call and webcast to be held today, May 15, at 8:30 AM EDT NEW YORK, May 15, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid") and Veris Health Inc. ("Veris"), and reported financial results for the first quarter ended March 31, 2026. Conference Call and Webcast The webcast will take place on Friday, May 15, 2026, at 8:30 AM and is accessible in the investor relations section of the Company's website at pavmed.com.

Lucid Diagnostics Inc. (LUCD) Q1 2026 Earnings Call Transcript

Lucid Diagnostics NASDAQ: LUCD reported first-quarter 2026 EsoGuard test volume above its pre-Medicare target range, while management said it continues to await a Medicare local coverage determination and is expanding efforts with the Department of Veterans Affairs, commercial payers and health systems.

Lucid Diagnostics Inc. (LUCD) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.16 per share a year ago.

Processed 3,177 EsoGuard ® tests and recognized 1Q26 revenue of $1.3 million, ending quarter with $45 million in proforma cash and a runway that extends into 2027 and past upcoming reimbursement milestones Conference call and webcast to be held today, May 14, at 8:30 AM EDT NEW YORK, May 14, 2026 /PRNewswire/ --  Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM) ("PAVmed"), today provided a business update for the Company and reported financial results for the first quarter ended March 31, 2026. Conference Call and Webcast The webcast will take place on Thursday, May 14, 2026, at 8:30 AM and will be accessible in the investor relations section of the Company's website at luciddx.com.

Lucid Diagnostics (LUCD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Conference Call and Webcast at 8:30 AM ET NEW YORK, May 1, 2026 /PRNewswire/ -- PAVmed Inc.  (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Friday, May 15, 2026, at 8:30 AM ET. During the call, Lishan Aklog, M.D.

Conference Call and Webcast at 8:30 AM ET NEW YORK, April 30, 2026 /PRNewswire/ --  Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Thursday, May 14, 2026, at 8:30 AM ET. During the call, Lishan Aklog, M.D.